Moderna announces positive results for Omicron vaccine / Photo: Joseph Prezioso - AFP
NYSE - LSE
| RYCEF | 2% | 14.49 | $ | |
| RBGPF | 0.08% | 75 | $ | |
| GSK | -0.36% | 37.425 | $ | |
| CMSC | 0.69% | 23.03 | $ | |
| VOD | 0.41% | 11.005 | $ | |
| RIO | 0.59% | 60.005 | $ | |
| SCS | 39.84% | 16.922 | $ | |
| NGG | 1.16% | 72.66 | $ | |
| RELX | 0.64% | 51.92 | $ | |
| BTI | 2.27% | 55.61 | $ | |
| AZN | 0.32% | 74.19 | $ | |
| BCC | -0.26% | 83.13 | $ | |
| SCU | 0% | 12.72 | $ | |
| BP | 1.96% | 32.385 | $ | |
| BCE | -0.66% | 23.415 | $ | |
| CMSD | 0.6% | 23.49 | $ | |
| JRI | 0.72% | 13.195 | $ |
Moderna announces positive results for Omicron vaccine
US biotech company Moderna on Wednesday announced positive results for a new vaccine that targets both the original Covid strain and Omicron.
This so-called "bivalent" vaccine was tested in a trial of more 850 adults, who had all received their first three doses of Moderna's original Spikevax vaccine.
Around half the group then received a fourth dose of Spikevax, while the rest received the bivalent vaccine.
Those who received the bivalent vaccine had significantly higher levels of neutralizing antibodies -- Y-shaped immune system proteins that block the virus -- against Omicron.
On average, these levels were around 75 percent higher in the group who got the bivalent vaccine as a fourth dose compared to those who got the original vaccine as a fourth dose. They also received slightly superior protection to the ancestral strain of Covid compared to Spikevax.
"We are thrilled," said Stephane Bancel, CEO of Moderna in a statement, adding he anticipated this vaccine would be the company's lead candidate for authorization as a booster this fall.
"We want to be as ready as early as August for shipping," he told investors in a call.
Stephen Hoge, the company's president, did concede that antibody levels would be lower against Omicron's sub variants that are now in circulation, but said he believed it was still a superior booster than repeating Spikevax.
The company doesn't yet have data on durability -- how the new vaccine booster will fare three months and six months out.
A panel of Food and Drug Administration experts will meet June 28 to discuss considerations and strategies for boosters in fall and winter.
I.Maier--SbgTB
